A few days ago, 3DBio Therapeutics, a New York-based biologics and bioprinting company, announced its AuriNovo, an investigational combination product using patients' own auricular cartilage cells to 3D-bioprint living, full-sized ear construct, received Orphan Drug designation from the United States Food and Drug Administration, a status assigned to treatments developed for rare conditions.
========================================================
部分内容来自网络,如有版权问题请与我们联系
未经许可,严禁转发。QQ交流群:688169419
========================================================